Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M8,094Revenue $M147Net Margin (%)-55.0Z-Score9.8
Enterprise Value $M7,737EPS $-0.6Operating Margin %-45.3F-Score2
P/E(ttm))0Cash Flow Per Share $-0.6Pre-tax Margin (%)-54.7Higher ROA y-yN
Price/Book23.410-y EBITDA Growth Rate %0Quick Ratio6.3Cash flow > EarningsY
Price/Sales46.95-y EBITDA Growth Rate %28.7Current Ratio6.4Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-11.3Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-25.3Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M118ROI % (ttm)-13.6Gross Margin Increase y-yN

Gurus Latest Trades with ISIS

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ISISGeorge Soros 2014-06-30 Sold Out $22.98 - $43.33
($31.44)
$ 68.51118%Sold Out0
ISISRon Baron 2014-06-30 Sold Out -0.01%$22.98 - $43.33
($31.44)
$ 68.51118%Sold Out0
ISISRon Baron 2014-03-31 Buy 0.01%$38.56 - $59
($48.28)
$ 68.5142%New holding, 45251 sh.45,251
ISISGeorge Soros 2014-03-31 Buy $38.56 - $59
($48.28)
$ 68.5142%New holding, 5539 sh.5,539
ISISGeorge Soros 2011-06-30 Sold Out $8.54 - $9.38
($8.92)
$ 68.51668%Sold Out0
ISISGeorge Soros 2011-03-31 Buy $8.57 - $10.35
($9.21)
$ 68.51644%New holding, 22300 sh.22,300
ISISJean-Marie Eveillard 2010-12-31 Sold Out -0.01%$8.05 - $10.51
($9.48)
$ 68.51623%Sold Out0
ISISJean-Marie Eveillard 2010-09-30 Buy 0.01%$7.775 - $10.07
($8.76)
$ 68.51682%New holding, 100000 sh.100,000
ISISGeorge Soros 2010-09-30 Sold Out $7.775 - $10.07
($8.76)
$ 68.51682%Sold Out0
ISISGeorge Soros 2010-06-30 Buy $8.84 - $11.13
($9.93)
$ 68.51590%New holding, 16100 sh.16,100
ISISJean-Marie Eveillard 2010-03-31 Sold Out -0.01%$8.66 - $11.76
($10.31)
$ 68.51564%Sold Out0
ISISJean-Marie Eveillard 2009-12-31 Buy 0.01%$9.94 - $14.16
($11.94)
$ 68.51474%New holding, 50000 sh.50,000
ISISKen Fisher 2008-12-31 Sold Out $10.37 - $15.82
($12.96)
$ 68.51429%Sold Out0
ISISKen Fisher 2008-09-30 Buy $14.24 - $19.08
($16.9)
$ 68.51305%New holding, 10050 sh.10,050
ISISJean-Marie Eveillard 2007-12-31 Sold Out $15.4 - $17.69
($16.7)
$ 68.51310%Sold Out0
ISISJean-Marie Eveillard 2007-09-30 Buy $9.74 - $14.97
($12.1)
$ 68.51466%New holding, 25000 sh.25,000
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ISIS is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


ISIS: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
CROOKE STANLEY TChairman and CEO 2015-01-16Sell9,054$67.960.91view
Geary Richard SSVP, Development 2015-01-16Sell1,543$67.960.91view
PARSHALL B LYNNECOO & Secretary 2015-01-16Sell4,093$67.960.91view
Monia Brett PSVP, Antisense Drug Discovery 2015-01-16Sell1,534$67.960.91view
HOUGEN ELIZABETH LSVP, Finance & CFO 2015-01-16Sell1,291$67.960.91view
O'NEIL PATRICK R.SVP, Legal & General Counsel 2015-01-16Sell1,291$67.960.91view
BENNETT C FRANKSVP, Antisense Research 2015-01-16Sell1,518$67.960.91view
Geary Richard SSVP, Development 2015-01-12Sell597$73.1-6.18view
CROOKE STANLEY TChairman and CEO 2015-01-09Sell11,000$73.57-6.78view
CROOKE STANLEY TChairman and CEO 2015-01-07Sell22,000$67.042.3view

Press Releases about ISIS :

    Quarterly/Annual Reports about ISIS:

    News about ISIS:

    Articles On GuruFocus.com
    Value vs. Growth: Is Jim Cramer Right about ISIS Pharmaceuticals? Dec 13 2014 
    Weekly CEO Sells Highlight: Keynote Systems Inc., Isis Pharmaceuticals, Coleman Cable Inc. Jul 01 2013 
    Isis Pharmaceuticals Inc. (ISIS) Director, COO B Lynne Parshall sells 17,200 Shares Dec 29 2010 
    Isis Pharmaceuticals Inc. (ISIS) Chairman, President, CEO Stanley T Crooke sells 32,000 Shares Dec 29 2010 
    Isis Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2010 
    Isis Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
    Guru Stocks at 52-Week Low: The Dun & Bradstreet Corp, FTI Consulting Inc, Terra Nitrogen Company L. Mar 07 2010 
    Guru Stocks at 52-Week Low: Dun & Bradstreet Corp, GameStop Corp, Dean Foods Company, SunPower Corp, Feb 21 2010 
    Weekly Guru Bargains Highlights: Weatherford International, MetroPCS Communications, Isis Pharmaceut Feb 13 2010 
    Weekly Guru Bargain Highlights: Sohu.com Inc, Isis Pharmaceuticals Inc, Netease.com Inc, Barclays PL Feb 06 2010 

    More From Other Websites
    Lightning Round: What to do with McDonald's Jan 28 2015
    These Top 10 Health Care Funds Are Full Of Vitality Jan 16 2015
    Isis Pharmaceuticals Earns Milestone Payment from Biogen - Analyst Blog Jan 15 2015
    Big Pharma faces up to new price pressure from aggressive insurers Jan 15 2015
    Big Pharma faces up to new price pressure from aggressive insurers Jan 15 2015
    Big Pharma faces up to new price pressure from aggressive insurers Jan 15 2015
    Isis Pharmaceuticals Earns $7M for Advancing ISIS-SMN Rx in Children With Spinal Muscular Atrophy Jan 14 2015
    'Mad Money' Lightning Round: You Should Stick With MasterCard Jan 14 2015
    Cramer: Waiting Out This Reversal Jan 14 2015
    Lightning Round: Wait on this rocket ship stock Jan 13 2015
    Jim Cramer's Top Stock Picks: ISIS CELG NPSP AA ACOR Jan 13 2015
    FDA places Arrowhead Hep B drug on partial hold, shares plunge Jan 12 2015
    Cramer's executive cut: CEOs on taxes, tech & biotech Jan 09 2015
    Alnylam and Isis Form New Agreement, Extending Decade-Long Partnership for Leadership in RNA... Jan 09 2015
    Alnylam and Isis Form New Agreement, Extending Decade-Long Partnership for Leadership in RNA... Jan 09 2015
    Alnylam and Isis Form New Agreement, Extending Decade-Long Partnership for Leadership in RNA... Jan 09 2015
    ISIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Jan 08 2015
    Drug trials, upgrades boost health-care sector Jan 08 2015
    Isis Pharmaceuticals Significantly Improves Upon 2014 Financial Guidance Jan 08 2015
    Isis Pharmaceuticals Significantly Improves Upon 2014 Financial Guidance Jan 08 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK